AVENIO ctDNA Analysis Kits V2 are a portfolio of three NGS liquid biopsy assays for oncology research. Using a streamlined workflow to evaluate ctDNA extracted from plasma, these assays provide an end-to-end solution for tumor profiling, longitudinal monitoring of tumor burden, and minimal residual disease (MRD) detection.